The university's researchers have developed a laboratory test that measures the body's response to infection in the blood, and can distinguish between bacterial and viral meningitis.
In PNAS this week: genetic diversity of MERS in African camels, centromere evolution in Cryptococcus, and more.
Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.
HER3 mRNA expression analysis can predict colorectal cancer patients with wild-type RAS tumors who will respond to panitumumab, US and UK researchers reported.
The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
In PLOS this week: gene-environment interactions affecting BMI, transposon mutagenesis study of UTI-linked bacteria, and more.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.